http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Global Blood Therapeutics (GBT) Reports Positive New Data on Oxbryta
-
GBT Presents Positive New Data on Oxbryta® (voxelotor) in Patients with Sickle Cell Disease at ASH Annual Meeting and Exposition
-
GBT Announces New Employment Inducement Grants
-
GBT Supports the ASH Research Collaborative’s Data Hub Sickle Cell Disease Program
-
GBT Supports the ASH Research Collaborative's Data Hub Sickle Cell Disease Program
-
GBT Announces Participation at the 4th Annual Evercore ISI HealthCONx Conference
-
GBT Announces Participation in Upcoming Investor Conferences
-
GBT Announces New Employment Inducement Grants
-
GBT Reports Third Quarter 2021 Financial Results
-
GBT Announces Six Data Presentations on Sickle Cell Disease at Upcoming 63rd American Society of Hematology (ASH) Annual Meeting & Exposition
-
GBT Wins Prestigious Prix Galien USA Award for Oxbryta® (voxelotor)
-
GBT to Announce Third Quarter 2021 Financial Results on Thursday, November 4
-
Pre-Open Stock Movers 10/07: (CEI) (RKLB) (APP) Higher; (OSMT) (LW) (DNA) Lower (more...)
-
GBT Announces New Employment Inducement Grants
-
After-Hours Stock Movers 10/06: (CEI) (RKLB) (APP) Higher; (OSMT) (DNA) Lower (more...)
-
GBT Announces Participation at the Cantor Global Healthcare Conference
-
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World
-
GBT Establishes The GBT Foundation to Improve the Health and Well-being of Underserved Patient Communities Around the World
-
GBT Announces New Employment Inducement Grants
-
GBT and Sickle Cell Disease Association of America to Host 10th Annual Sickle Cell Disease (SCD) Therapeutics Conference
-
Global Blood Therapeutics (GBT) Announces U.S. FDA Accepts for Priority Review sNDA for Oxbryta for Treatment of Sickle Cell Disease in Children Ages 4 to 11
-
U.S. FDA Accepts for Priority Review Supplemental New Drug Application for Oxbryta® (voxelotor) for the Treatment of Sickle Cell Disease in Children Ages 4 to 11
-
GBT Announces Participation in Upcoming Investor Conferences
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Participation at the Wedbush PacGrow Healthcare Conference
-
GBT Reports Second Quarter 2021 Financial Results
-
GBT to Announce Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
-
GBT Provides Regulatory and Pipeline Updates in Sickle Cell Disease (SCD)
-
GBT Announces New Employment Inducement Grants
-
GBT Awards $450,000 in ACCEL Grants to Improve Access to Care in Sickle Cell Disease
-
Global Blood Therapeutics' (GBT) Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
-
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
-
GBT’s Voxelotor is First Sickle Cell Disease Treatment to Receive Promising Innovative Medicine (PIM) Designation in the UK
-
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
-
New Data Supporting the Potential Use of Oxbryta® (voxelotor) in Children Ages 4 to 11 Years with Sickle Cell Disease Presented at European Hematology Association 2021 Virtual Congress
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Participation at the Goldman Sachs 42nd Annual Global Healthcare Conference
-
Global Blood Therapeutics (GBT) Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
-
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
-
GBT Announces Upcoming Data Presentations at European Hematology Association (EHA) 2021 Virtual Congress
-
GBT Announces New Employment Inducement Grants
-
GBT Announces Participation in Upcoming Investor Conferences
-
GBT Reports First Quarter 2021 Financial Results
-
GBT and Sickle Cell Disease Association of America Kick Off “Lift Every Voice to Shine the Light on Sickle Cell” Spoken Word Contest in Honor of World Sickle Cell Day 2021
-
GBT to Announce First Quarter 2021 Financial Results on Wednesday, May 5, 2021
-
Global Blood Therapeutics (GBT) 72-Week Results from Phase 3 HOPE Study of Oxbryta Tablets Published in The Lancet Haematology
-
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sic
-
Complete 72-Week Results from Phase 3 HOPE Study of Oxbryta® (voxelotor) Tablets Published in The Lancet Haematology Show Significantly Improved Hemoglobin, Hemolysis and Overall Health Status in Sic
-
GBT Announces New Employment Inducement Grants
-
GBT Appoints Alexis A. Thompson, M.D., M.P.H., to Board of Directors

